Evidence map›Paper›PMID 35941660›Full record

ArticleArthritis research & therapy2022

Identification of TMEM129, encoding a ubiquitin-protein ligase, as an effector gene of osteoarthritis genetic risk.

Abby Brumwell, Guillaume Aubourg, Juhel Hussain, Eleanor Parker, David J Deehan, Sarah J Rice, John Loughlin

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Abby BrumwellNewcastle University, Biosciences Institute, International Centre for Life, Newcastle upon Tyne, UK.ORCID 0000-0002-1287-7905
Guillaume AubourgNewcastle University, Biosciences Institute, International Centre for Life, Newcastle upon Tyne, UK.
Juhel HussainNewcastle University, Biosciences Institute, International Centre for Life, Newcastle upon Tyne, UK.
Eleanor ParkerNewcastle University, Biosciences Institute, International Centre for Life, Newcastle upon Tyne, UK.
David J DeehanFreeman Hospital, Newcastle University Teaching Hospitals NHS Trust, Newcastle upon Tyne, UK.
Sarah J RiceNewcastle University, Biosciences Institute, International Centre for Life, Newcastle upon Tyne, UK.ORCID 0000-0003-3343-5986
John LoughlinNewcastle University, Biosciences Institute, International Centre for Life, Newcastle upon Tyne, UK. john.loughlin@newcastle.ac.uk.ORCID 0000-0003-2018-3361
Centre for Life · GBFreeman Hospital · GB

Funding

Department of HealthMedical Research Council MR/P020941/1Medical Research Council MR/R502182/1Versus Arthritis 20771Versus Arthritis 22615Versus Arthritis JXR 10641
6 · The paper itself

Abstract

backgroundOsteoarthritis is highly heritable and genome-wide studies have identified single nucleotide polymorphisms (SNPs) associated with the disease. One such locus is marked by SNP rs11732213 (T > C). Genotype at rs11732213 correlates with the methylation levels of nearby CpG dinucleotides (CpGs), forming a methylation quantitative trait locus (mQTL). This study investigated the regulatory activity of the CpGs to identify a target gene of the locus.

methodsNucleic acids were extracted from the articular cartilage of osteoarthritis patients. Samples were genotyped, and DNA methylation was quantified by pyrosequencing at 14 CpGs within a 259-bp interval. CpGs were tested for enhancer effects in immortalised chondrocytes using a reporter gene assay. DNA methylation at the locus was altered using targeted epigenome editing, with the impact on gene expression determined using quantitative polymerase chain reaction.

resultsrs11732213 genotype correlated with DNA methylation at nine CpGs, which formed a differentially methylated region (DMR), with the osteoarthritis risk allele T corresponding to reduced levels of methylation. The DMR acted as an enhancer and demethylation of the CpGs altered expression of TMEM129. Allelic imbalance in TMEM129 expression was identified in cartilage, with under-expression of the risk allele.

conclusionsTMEM129 is a target of osteoarthritis genetic risk at this locus. Genotype at rs11732213 impacts DNA methylation at the enhancer, which, in turn, modulates TMEM129 expression. TMEM129 encodes an enzyme involved in protein degradation within the endoplasmic reticulum, a process previously implicated in osteoarthritis. TMEM129 is a compelling osteoarthritis susceptibility target.

Indexed as

OsteoarthritisCpG IslandsDNA MethylationHumansPolymorphism, Single NucleotideQuantitative Trait LociUbiquitin-Protein LigasesTMEM129 protein, humanUbiquitin-Protein LigasesDNA methylationEpigeneticsEpigenome editingGeneticsTMEM129

Identifiers

PMID35941660
PMCPMC9358880
OpenAlexW4290614495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.